Related Experiment Video
Updated: Dec 29, 2025
10:04
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
1.4K
DC-CIK as a widely applicable cancer immunotherapy
Shuo Wang1, Xiaoli Wang1, Xinna Zhou1
1Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Expert Opinion on Biological Therapy
|February 9, 2020
Summary
Dendritic cell-cytokine-induced killer (DC-CIK) cell therapy offers a promising, non-MHC dependent approach for cancer treatment. This immunotherapy is safe and effective alone or combined with other treatments for various malignancies.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Immunotherapy, including immune checkpoint inhibition, is a standard cancer treatment.
- Adoptive cell transfer therapies aim to provide activated immune cells for direct tumor destruction.
- Dendritic cell-cytokine-induced killer (DC-CIK) cell therapy is a widely applicable, non-MHC dependent cellular therapy.
Purpose of the Study:
- To summarize clinical data from studies involving DC-CIK therapy.
- To discuss future research directions for DC-CIK cell therapy.
- To highlight the potential of DC-CIK as a versatile anti-cancer treatment.
Main Methods:
- Review of clinical data from DC-CIK therapy studies.
- Analysis of safety and efficacy data.
- Exploration of combination therapy outcomes.
Main Results:
- DC-CIK therapy has demonstrated safety and efficacy in patients with various tumor types.
- Clinical responses have been observed in patients receiving DC-CIK therapy.
- The therapy is highly efficient to produce from individual patients.
Conclusions:
- DC-CIK cell therapy is a versatile and effective treatment option for a wide range of cancers.
- This cellular therapy synergizes well with other anti-cancer modalities, including chemotherapy and immunotherapy.
- Further research into DC-CIK therapy holds promise for advancing cancer treatment strategies.
Related Concept Videos
01:30Cancer Vaccines
880
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
880
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:15M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K